A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Trial Details

NCT ID
NCT07824882
Phase
PHASE2
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HS-20093 for Injection
  • Adebrelimab Injection
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Age ≥18 years at the time of informed consent form (ICF) signature, either sex.
  • Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent, and commitmen…
  • Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung can…
  • Presence of at least one measurable target lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →